Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced an exclusive licensing and manufacturing agreement with LyoGenesis Plus ("LyoGenesis"), a cGMP ...
Vector Science and Therapeutics Corp. (TSXV: PAIN), a pharmaceutical-grade peptide and precision drug delivery company, today ...
Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the filing of a provisional patent application covering a ...
Newly Formed Sports Medicine Division Taps Experienced Leader to Build Elite Athlete Network and Distribution Channel MEQUON, Wis., June 8, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp.
Year MLB Veteran and 2016 World Series Champion Joins Valor, Vector's Athlete Platform, to Make Sure the Next Generation Plays Longer and Hurts Less MEQUON, Wis., June 12, 2026 /PRNewswire/ -- Vector ...
LODI, Wis., Oct. 2, 2025 /CNW/ -- Vector Science & Therapeutics today announced the appointment of Tabitha Hendren as Director, Engineering and Design. Hendren will report to Chief Technology Officer ...
Vector Science and Therapeutics Corp. (TSXV: PAIN), a pharmaceutical-grade peptide and precision drug delivery company, today announced that ...
Proprietary Magnetic Patch System Delivers Regenerative Peptides to Targeted Tissue Without Injection, with Built-In Confirmation of Successful Delivery MEQUON, Wis.